ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Employees

42,250

Sector

Biotechnology & Medical Research

Calendar

2025-02-18 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-06	217.47 $	+3.81%	1,290,997
24-12-05	209.49 $	-2.34%	878,821
24-12-04	214.50 $	+0.71%	1,039,423
24-12-03	212.99 $	-0.27%	1,349,015
24-12-02	213.56 $	+1.57%	1,662,390

Delayed Quote Nasdaq, December 06, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

217.47USD

Average target price

276.06USD

Spread / Average Target

+26.94%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-06 pm EST			5-day change	1st Jan Change
217.47 ^USD	+3.81%		+3.43%	-23.17%

Dec. 02	Nephron Upgrades ICON to Buy, Price Target is $280	MT
Nov. 25	Fed minutes and inflation data set to stir Thanksgiving week

Capitalization	17.95B 16.99B 15.75B 14.09B 25.38B 1,521B 28.1B 196B 72.45B 625B 67.44B 65.95B 2,692B	P/E ratio 2024 *	25x	P/E ratio 2025 *	19.9x
Enterprise value	20.58B 19.47B 18.05B 16.14B 29.09B 1,743B 32.2B 225B 83.03B 716B 77.3B 75.58B 3,085B	EV / Sales 2024 *	2.49x	EV / Sales 2025 *	2.29x
Free-Float	-	Yield 2024 *	-	Yield 2025 *	-

Nephron Upgrades ICON to Buy, Price Target is $280	Dec. 02	MT
Fed minutes and inflation data set to stir Thanksgiving week	Nov. 25
Analyst recommendations: Five Below, Robinhood, Snowflake, Block, Ge Vernova...	Nov. 25
ICON Public Limited Company Reiterates Earnings Guidance for the Year 2024 and Provides Revenue Guidance for 2025	Nov. 21	CI
ICON Public Seeks M&A	Nov. 21	CI
ICON Public Limited Company Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 08:00 AM	Nov. 21
ICON's 2026 High-Single-Digit Growth Potential Intact If Customer Hurdles Cleared, UBS Says	Oct. 25	MT
UBS Adjusts Price Target on ICON to $290 From $380, Maintains Buy Rating	Oct. 25	MT
ICON Public Limited Company announces an Equity Buyback for $250 million worth of its shares.	Oct. 25	CI
ICON Shares Decline as Baird Downgrade Follows Q3 Miss	Oct. 24	MT
Technology Stocks Rise After Tesla Earnings as US Equity Futures Trade Mixed Pre-Bell	Oct. 24	MT
ICON Seeks M&A	Oct. 24	CI
ICON Public Limited Company, Q3 2024 Earnings Call, Oct 24, 2024	Oct. 24

Nephron Upgrades ICON to Buy, Price Target is $280	Dec. 02	MT
Analyst recommendations: Five Below, Robinhood, Snowflake, Block, Ge Vernova...	Nov. 25
UBS Adjusts Price Target on ICON to $290 From $380, Maintains Buy Rating	Oct. 25	MT
Baird Downgrades ICON to Neutral From Outperform, Price Target is $340	Oct. 24	MT
Analyst recommendations: P&G, Enphase, AT&T, Deckers Outdoor, ServiceNow...	Oct. 24

ICON Public Limited Company Stock

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Valuation: ICON Public Limited Company

Chart: ICON Public Limited Company

Latest news: ICON Public Limited Company

Last Transcript: ICON Public Limited Company

Analysts' recommendations: ICON Public Limited Company

Press Releases: ICON Public Limited Company

News in other languages: ICON Public Limited Company

Quotes and Performance

Course Extremes

Managers and Directors: ICON Public Limited Company

ETFs: ICON Public Limited Company

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Law Offices of Howard G. Smith Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors	Dec. 06	PR
The Law Offices of Frank R. Cruz Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors	Dec. 05	PR
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption	Dec. 05	BU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors	Nov. 27	BU
Law Offices of Howard G. Smith Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors	Nov. 26	BU

RECOMENDACIONES DE LOS ANALISTAS EE.UU.: Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	Feb. 21
MÄRKTE USA/Wall Street mit deutlichen Aufschlägen - Nasdaq +1,0%	21-02-24
ICON Public : compra PRA Health en 12.000 millones dólares, busca crecer en sector pruebas clínicas virtuales	21-02-24
MÄRKTE USA/Börsen mit Aufschlägen - auch Nasdaq im Plus	21-02-24
MÄRKTE USA/Steigende Anleiherenditen bremsen Wall Street	21-02-24

1 day	+3.81%
1 week	+3.43%
Current month	+3.43%
1 month	+1.18%
3 months	-28.11%
6 months	-31.89%
Current year	-23.17%

Director	Title	Age	Since
Stephen Cutler CEO	Chief Executive Officer	63	2017-02-28
Nigel Bernard John Clerkin DFI	Director of Finance/CFO	51	2024-09-30
Gregory Licholai CTO	Chief Tech/Sci/R&D Officer	59	2021-10-31

Manager	Title	Age	Since
John Climax CHM	Chairman	71	2002-10-31
Ciaran Murray CHM	Chairman	61	2017-02-28
Stephen Cutler BRD	Director/Board Member	63	2015-11-24

Name	Weight	AuM	1st Jan change	Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	3.68%	2 M€	-.--%
BMO MSCI INNOVATION INDEX ETF - CAD	1.28%	7 M€	-.--%	-
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD	0.91%	4 M€	+20.69%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ICON PUBLIC LIMITED COMPANY	+3.81%	+3.43%	-20.18%	-21.89%	17.95B
LONZA GROUP AG	+0.42%	-0.80%	+58.63%	-29.66%	43B
IQVIA HOLDINGS INC.	+1.35%	+0.89%	-5.88%	-25.56%	36.78B
CELLTRION, INC.	-0.50%	-3.69%	+7.39%	-7.93%	26.11B
MODERNA, INC.	+3.49%	+3.20%	-44.67%	-84.32%	17.1B
UNITED THERAPEUTICS CORPORATION	-1.26%	-0.22%	+52.98%	+90.61%	16.5B
BIO-TECHNE CORPORATION	+0.84%	-1.13%	+9.08%	-38.08%	11.84B
MEDPACE HOLDINGS, INC.	+2.40%	+2.91%	+23.78%	+64.07%	10.87B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.14%	-3.64%	-6.19%	-47.59%	9.81B
QIAGEN N.V.	-0.02%	-0.02%	+0.83%	-23.09%	9.65B
Average	+1.07%	+0.22%	+7.58%	-12.34%	19.96B
Weighted average by Cap.	+1.00%	+0.15%	+12.82%	-16.06%

	2024 *	2025 *
Net sales	8.28B 7.83B 7.26B 6.49B 11.7B 701B 12.95B 90.33B 33.39B 288B 31.09B 30.4B 1,241B	8.53B 8.07B 7.48B 6.69B 12.06B 722B 13.35B 93.07B 34.41B 297B 32.03B 31.32B 1,278B
Net income	730M 691M 640M 573M 1.03B 61.82B 1.14B 7.97B 2.95B 25.4B 2.74B 2.68B 109B	919M 870M 806M 721M 1.3B 77.82B 1.44B 10.03B 3.71B 31.97B 3.45B 3.38B 138B
Net Debt	2.62B 2.48B 2.3B 2.06B 3.71B 222B 4.1B 28.63B 10.58B 91.26B 9.85B 9.63B 393B	1.58B 1.5B 1.39B 1.24B 2.23B 134B 2.47B 17.25B 6.38B 55.01B 5.94B 5.81B 237B